| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.07. | ImmuCell reports preliminary Q2 sales increase of 11.5% to $7.2M | 1 | Seeking Alpha | ||
| 09.07. | ImmuCell reports 11.5% sales increase in second quarter | 1 | Investing.com | ||
| 09.07. | ImmuCell Corporation: ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results | 108 | GlobeNewswire (Europe) | PORTLAND, Maine, July 09, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products... ► Artikel lesen | |
| 09.07. | IMMUCELL CORP /DE/ - 8-K, Current Report | 1 | SEC Filings | ||
| IMMUCELL Aktie jetzt für 0€ handeln | |||||
| 17.06. | ImmuCell: Aktionäre billigen auf jährlicher Hauptversammlung alle Vorschläge | 2 | Investing.com Deutsch | ||
| 10.06. | IMMUCELL CORP /DE/ - 8-K, Current Report | 3 | SEC Filings | ||
| 15.05. | ImmuCell outlines capacity expansion plan backed by $2M settlement while focusing on First Defense | 5 | Seeking Alpha | ||
| 15.05. | Mitschrift des Earnings Call: ImmuCell erreicht mit Umsatzsprung im Q1 2026 wichtigen Meilenstein | 1 | Investing.com Deutsch | ||
| 14.05. | IMMUCELL CORP /DE/ - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 13.05. | IMMUCELL CORP /DE/ - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 13.05. | Here's Why ImmuCell Corporation (ICCC) is Emerging as an Intriguing Micro-Cap Opportunity | 2 | Insider Monkey | ||
| 08.05. | IMMUCELL CORP /DE/ - 8-K, Current Report | - | SEC Filings | ||
| 15.04. | ImmuCell: Board Appointments And Governance Changes Advance Innovation Strategy | 3 | pulse2.com | ||
| 13.04. | ImmuCell appoints two directors, expands to 7-member board | 1 | Investing.com | ||
| 13.04. | ImmuCell Corporation: ImmuCell Bolsters its Innovation Strategy with Appointments of Dr. Gilles Guillemette and Dr. Anthony DiMarco to the Board, and Moves to a Smaller Board of Independent Directors | 725 | GlobeNewswire (Europe) | PORTLAND, Maine, April 13, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops and markets products to improve... ► Artikel lesen | |
| 09.04. | ImmuCell sees preliminary Q1 revenue of $10.4M | 2 | Seeking Alpha | ||
| 08.04. | ImmuCell Q1 sales jump 28.4% to $10.4M, led by Tri-Shield demand | 1 | Seeking Alpha | ||
| 08.04. | ImmuCell reports 28% sales increase in first quarter | 1 | Investing.com | ||
| 08.04. | ImmuCell Corporation: ImmuCell Announces a 28.4% Increase in Product Sales in Q1 of 2026, based on Preliminary, Unaudited Sales Results | 412 | GlobeNewswire (Europe) | PORTLAND, Maine, April 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) ("ImmuCell" or the "Company"), an animal health biologics company that develops, manufactures and markets products... ► Artikel lesen | |
| 08.04. | IMMUCELL CORP /DE/ - 8-K, Current Report | - | SEC Filings |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 3,464 | +0,93 % | Übernahmekandidaten! Steyr Motors nach 20 %-Sprung! RE Royalties spannend! Und was macht Evotec? | Um 20 % ist die Aktie von Steyr Motors in der vergangenen Woche kurzzeitig explodiert. Grund waren Übernahmespekulationen durch einen Drohnen- und Robotikspezialisten aus den USA. Die Gespräche wurden... ► Artikel lesen | |
| BB BIOTECH | 55,70 | +1,27 % | Edison Investment Research Limited: Edison issues report on BB Biotech (BION) | Edison Investment Research Limited
Edison issues report on BB Biotech (BION) 28-Jul-2026 / 14:20 GMT/BST
The issuer is solely responsible for the content of this announcement.
... ► Artikel lesen | |
| QIAGEN | 36,460 | +0,89 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| AMGEN | 355,85 | +0,13 % | Ihre wichtigsten Termine: Q2-Updates von SpaceX, Bayer, Biontech, Spotify, Pfizer, Continental, Merck & Co | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 05:00 Uhr, Großbritannien:... ► Artikel lesen | |
| NOVAVAX | 6,850 | -0,29 % | Novavax, Inc.: Novavax Reports Second Quarter 2026 Financial Results and Operational Highlights | Reported total revenue of $57 million for the second quarter of 2026 and raised full-year 2026 Revenue Framework
Improved GAAP Combined R&D and SG&A expense... ► Artikel lesen | |
| BIOGEN | 178,40 | -0,82 % | Biogen Inc.: Biogen Completes Acquisition of RayThera Inc. | Lead program now in Phase 1 developmentCAMBRIDGE, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the completion of the acquisition of RayThera Inc., a privately... ► Artikel lesen | |
| ILLUMINA | 162,12 | -0,31 % | Devyser Diagnostics AB: Devyser signs first commercial reagent rental agreement under Illumina collaboration in Italy | Devyser, a global leader in advanced molecular diagnostics, today announced the first commercial agreement under its Systems Integrator collaboration with Illumina. The agreement, signed with an Italian... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 675,00 | -0,49 % | Megatrend Folger: Regeneron zündet den Kursturbo | Regeneron hat mit seinen jüngsten Quartalszahlen die Erwartungen deutlich übertroffen. Dupixent, Eylea in der höheren Dosierung und Libtayo wachsen kräftig, während die Aktie ihre monatelange Schwächephase... ► Artikel lesen | |
| OCUGEN | 1,094 | -0,91 % | Ocugen Provides Business Update with Second Quarter 2026 Financial Results | Conference Call and Webcast Today at 8:30 a.m. ET Received U.S. Food and Drug Administration (FDA) clearance to initiate OCU410 Phase 3 trial for geographic atrophy (GA), secondary to dry age-related... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 0,580 | +1,05 % | Inovio Pharmaceuticals, Inc.: INOVIO Announces Pricing of $20.0 Million Public Offering | PLYMOUTH MEETING, Pa., July 29, 2026 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing... ► Artikel lesen | |
| INFLARX | 1,585 | -0,69 % | InflaRx N.V.: InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones | Announced advancement of izicopan in ANCA-associated vasculitis (AAV) and select renal diseases; clinical preparations ongoing as plannedInitiated feasibility assessment for broadened strategy for... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 10,300 | -0,39 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates | Positive Phase 3 HAELO clinical data for lonvo-z in HAE presented at EAACI and published in New England Journal of MedicineAnticipate FDA acceptance of BLA for lonvo-z in second half of 2026 and U.S.... ► Artikel lesen | |
| COSCIENS BIOPHARMA | 4,275 | +0,23 % | COSCIENS Biopharma Inc. Completes Share Capital Amendment | TORONTO, ONTARIO, July 03, 2026 (GLOBE NEWSWIRE) -- COSCIENS Biopharma Inc. (TSX: CSCI) (OTCQB: CSCIF) ("COSCIENS" or the "Company"), today announced the previously announced consolidation (the "Consolidation")... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| BIOCRYST PHARMACEUTICALS | 8,172 | +0,79 % | Biocryst outlines $690M-$715M 2026 total revenue guidance with operating costs at $420M-$440M |